| Research background and objectiveOvarian cancer has a high degree of malignancy,insidious onset,low early diagnosis rate and poor prognosis,and the mortality rate of advanced tumor is as high as 90%.Most ovarian cancers originate from the epithelium,and serous ovarian cancer is the most common histologic type.Tumor reduction surgery combined with paclitaxel and platinum-based chemotherapy is the main treatment for ovarian cancer,which is often effective in early stage for some patients,but the recurrence rate is as high as 70%.Molecular targeted drugs have been widely used in various tumor therapies because of their remarkable efficacy and few side effects.Research and development of new targeted drugs is the general direction to solve the tumor problems in the future.In this study,we evaluated the feasibility and clinical significance of TRIM47 as a therapeutic target for serous ovarian cancer by detecting the expression of TRIM47 in the tissues of serous ovarian cancers and its relationship with clinicopathological parameters and prognosis.Materials and Methods1.The mRNA expression levels of TRIM47 in ovarian cancer tissues and normal ovarian tissues were analyzed by searching GEPIA and Oncomine online databases;The association between TRIM47 expression and progression-free survival(PFS)and overall survival(OS)of ovarian cancer was investigated by Kaplan-Meier database.2.Tissue chips containing 71 cases of serous ovarian cancer were purchased from Shanghai Xinchao Biotechnology Co.,Ltd.,and 20 cases of normal ovarian tissues from benign tumors of the uterus treated by the Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine from 2015 to 2018 were collected as control.Immunohistochemistry(IHC)was used to detect the different expressions of TRIM47 protein in serous ovarian cancer and normal ovarian tissues.3.By using the SPSS 19.0 statistical software package and GraphPad Prism8.0.1 for data analysis,organization through the analysis of the chi-square test or Fisher’s exact test TRIM47 high expression and clinicopathological features of serous ovarian cancer,the relationship between Kaplan Meier-through single factor analysis whether TRIM47 with serous ovarian cancer disease-free survival(DFS)and overall survival(OS),further by Cox multi-factor analysis of independent risk factors affecting prognosis of serous ovarian cancer.Results1.The expression of TRIM47 in ovarian cancer tissues was significantly higher than that in normal ovarian tissues by GEPIA online database retrieval analysis(P<0.05).Kaplan-Meier database showed that in patients with advanced(Ⅲ+Ⅳ)serous ovarian cancer,patients with higher TRIM47mRNA transcription level had a worse prognosis than those with lower TRIM47 transcription level,mainly manifested in a shorter progression-free survival(P<0.05),but there was no significant association between TRIM47 expression level and ovarian cancer OS(P>0.05).2.Compared with normal ovarian tissues,TRIM47 was significantly higher expressed in serous ovarian cancer tissues,and the expression difference between the two tissues was statistically significant(P<0.05).3.The positive expression of TRIM47 protein was correlated with clinical stage,pathological grade,histological type,Ki67 expression,PD-L1 expression,recurrence or survival status(P<0.05),but not with age,tumor size,lymph node metastasis,distant metastasis or EGFR expression(P>0.05).Kaplan-Meier test showed that the disease-free survival(DFS)and overall survival(OS)of serous ovarian cancer patients with high TRIM47 protein expression were significantly lower than those with low TRIM47 protein expression(P<0.05).Cox multivariate analysis showed that high expression of TRIM47,distant metastasis,FIGO stage(stage Ⅲ-Ⅳ),tumor size>8cm,and age>55 years old were independent risk factors for poor OS in patients with serous ovarian cancer.ConclusionTRIM47 is highly expressed in serous ovarian cancer and may be used as an indicator to judge the prognosis of this type of patients. |
PDF Full Text Request